Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy.
about
The role of CD95 and CD95 ligand in cancerApoptosis in animal models of virus-induced diseaseIncreased Fas ligand expression of CD4+ T cells by HCV core induces T cell-dependent hepatic inflammation.Transfection of apoptosis related gene Fas ligand in human hepatocellular carcinoma cells and its significance in apoptosis.Cell death and cell death responses in liver disease: mechanisms and clinical relevanceConsidering Fas ligand as a target for therapy.Hepatocellular carcinoma: therapy and prevention.Fibroblast growth factor-4 and hepatocyte growth factor induce differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocytes.Evolving therapies in the treatment of hepatocellular carcinomaAdvances in prevention and diagnosis of hepatocellular carcinoma.An overview of hepatocellular carcinoma study by omics-based methods.Apoptosis and necrosis in the liverCaspase inhibitors for the treatment of hepatitis C.Targeting apoptosis in autoimmune hepatitis.Intra-hepatic Depletion of Mucosal Associated Invariant T cells in Hepatitis C Virus-induced Liver Inflammation.Suppression of human hepatoma growth in vivo by a monoclonal antibody against a Mr 45,000 protein.Fas Ligand Has a Greater Impact than TNF-α on Apoptosis and Inflammation in Ischemic Acute Kidney InjuryGene expression profiling of hepatocarcinogenesis in a mouse model of chronic hepatitis B.Anti-Inflammatory Activity Is a Possible Mechanism by Which the Polyherbal Formulation Comprised of Nigella sativa (Seeds), Hemidesmus indicus (Root), and Smilax glabra (Rhizome) Mediates Its Antihepatocarcinogenic EffectsInterferon-gamma-mediated hepatocarcinogenesis in mice treated with diethylnitrosamine.Senescence and cell death in chronic liver injury: roles and mechanisms underlying hepatocarcinogenesis.Increased killer B cells in chronic HCV infection may lead to autoimmunity and increased viral load.Combined effects of an antioxidant and caspase inhibitor on the reversal of hepatic fibrosis in rats.Active Role of the Necrotic Zone in Desensitization of Hypoxic Macrophages and Regulation of CSC-Fate: A hypothesis.
P2860
Q26995847-D24FD2E0-F2F3-49A7-8F01-F9FBA156FFB5Q27490338-09339016-1B86-4E55-ACEC-9A2350D8AF47Q30436833-8B845CBF-6233-48D7-A224-94CDF70B7437Q31162726-8F0AA35B-6DB3-430C-B8FC-9FA39FFDD8EAQ35938040-DC3D005F-A5CB-4B7D-A24A-8F3C3D856517Q36066300-210E1E1A-9940-4DAE-BE8E-E2F722D97D4CQ36377949-D8D51C5A-6225-4C18-B350-FBF0D75A0826Q36497118-95C8A564-4514-47D8-B3A6-C3CAFFDF6D65Q37290714-C7ED3B94-F8B7-4583-B75C-AB4D8FFFD5D2Q37345951-82BE52FC-055E-4008-B116-4A634929FC1EQ37364456-62E1B52C-C80E-4D3F-8987-E6106FAEE388Q37403072-2C5EF150-9658-4200-A0F6-6BD358F2944CQ37560275-795C2955-7AC8-40A1-9F2C-73CE23B65866Q38231217-5251043D-2C53-4957-95C0-DDEBA72A15CAQ40093638-FBA6AB2D-7C00-4BF9-828B-B061A3CD85EBQ40197733-38F41A05-9D67-4E32-AECC-688851FC24DEQ41830820-9BE389B3-ECC0-4BBE-861F-60DD275672B5Q41926688-FFB9DFE7-3A29-41D4-9FED-1CF3F97F1AE2Q42397962-FCDA0504-D5C3-4E17-B8C5-9A01424A6C8AQ46375786-D6195895-A5A0-4225-876B-583C309C9DADQ52371276-BFE7D967-1DE8-48D0-BAA5-61469648D715Q52583000-546B78E0-BDA5-4D96-B8BB-53ED5DCB03CBQ53315561-F000D7D3-8F74-46E8-847A-8FDBBBC549C1Q55479842-CA8F46E5-D53C-4D65-9967-2BEF953CD9E9
P2860
Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@ast
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@en
type
label
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@ast
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@en
prefLabel
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@ast
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@en
P2093
P2860
P356
P1476
Prevention of hepatocellular c ...... i-fas ligand antibody therapy.
@en
P2093
Hiroko Tsutsui
Kenichi Kobayashi
Kenji Nakanishi
Shuichi Kaneko
Takashi Momoi
Takashi Suda
Yasunari Nakamoto
P2860
P304
P356
10.1084/JEM.20020633
P407
P577
2002-10-01T00:00:00Z